Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report released on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on RVNC. Stifel Nicolaus dropped their price target on shares of Revance Therapeutics from $24.00 to $20.00 and set a buy rating on the stock in a research report on Friday, August 9th. Piper Sandler lowered shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research report on Monday, August 12th. Needham & Company LLC lowered shares of Revance Therapeutics from a moderate buy rating to a hold rating in a research report on Tuesday, August 13th. Barclays restated an equal weight rating and set a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Finally, HC Wainwright lowered shares of Revance Therapeutics from a strong-buy rating to a hold rating in a research report on Tuesday, August 13th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Revance Therapeutics currently has a consensus rating of Hold and a consensus price target of $10.50.

Revance Therapeutics Price Performance

NASDAQ:RVNC opened at $5.99 on Friday. The firm has a market capitalization of $625.65 million, a P/E ratio of -1.65 and a beta of 1.00. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $14.24. The company’s fifty day moving average price is $5.24 and its 200-day moving average price is $4.29.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. The firm’s revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.80) EPS.

Institutional Trading of Revance Therapeutics

Several institutional investors have recently modified their holdings of RVNC. Certuity LLC acquired a new stake in shares of Revance Therapeutics in the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Revance Therapeutics in the second quarter worth about $33,000. Hsbc Holdings PLC purchased a new position in shares of Revance Therapeutics in the second quarter worth about $38,000. Nisa Investment Advisors LLC lifted its stake in shares of Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 18,077 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in shares of Revance Therapeutics by 52.5% in the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 7,628 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.